Treatment of AML patients with a FLT3 inhibitor as a single agent is not likely to lead to a complete remission and therefore combination with other agents can potentially provide more clinical benefit, as has previously been observed.6 A benefit of combined use of FLT3 inhibitors with other agents is overriding of some forms of drug resistance. This evidence concerns the gene FLT3 and acute myeloid leukemia.